




Instance: composition-en-bbd22ba876ae7309a2b1061a1e9bb063
InstanceOf: CompositionUvEpi
Title: "Composition for vantavo Package Leaflet"
Description:  "Composition for vantavo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/09/572/001 – 2 tablets"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpbbd22ba876ae7309a2b1061a1e9bb063)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vantavo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What VANTAVO is and what it is used for </li>
<li>What you need to know before you take VANTAVO </li>
<li>How to take VANTAVO </li>
<li>Possible side effects </li>
<li>How to store VANTAVO </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vantavo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vantavo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is VANTAVO? 
VANTAVO is a tablet containing the two active substances, alendronic acid (commonly called 
alendronate) and colecalciferol known as vitamin D3. What is alendronate? 
Alendronate belongs to a group of non-hormonal medicines called bisphosphonates. Alendronate 
prevents the loss of bone that occurs in women after they have been through the menopause, and helps 
to rebuild bone. It reduces the risk of spine and hip fractures.  </p>
<p>What is vitamin D? 
Vitamin D is an essential nutrient, required for calcium absorption and healthy bones. The body can 
only absorb calcium properly from our food if it has enough vitamin D. Very few foods contain 
vitamin D. The main source is through exposure to summer sunlight, which makes vitamin D in our 
skin. As we get older our skin makes less vitamin D. Too little vitamin D may lead to bone loss and 
osteoporosis. Severe vitamin D deficiency may cause muscle weakness which can lead to falls and a 
greater risk of fractures. </p>
<p>What is VANTAVO used for? 
Your doctor has prescribed VANTAVO to treat your osteoporosis and because you are at risk of 
vitamin D insufficiency. It reduces the risk of spine and hip fractures in women after menopause. </p>
<p>What is osteoporosis? 
Osteoporosis is a thinning and weakening of the bones. It is common in women after the menopause. 
At the menopause, the ovaries stop producing the female hormone, oestrogen, which helps to keep a 
woman s skeleton healthy. As a result, bone loss occurs and bones become weaker. The earlier a 
woman reaches the menopause, the greater the risk of osteoporosis.  </p>
<p>Early on, osteoporosis usually has no symptoms. If left untreated, however, it can result in broken 
bones. Although these usually hurt, breaks in the bones of the spine may go unnoticed until they cause 
height loss. Broken bones can happen during normal, everyday activity, such as lifting, or from minor 
injury that would not generally break normal bone. Broken bones usually occur at the hip, spine, or 
wrist and can lead not only to pain but also to considerable problems like stooped posture ( dowager s 
hump ) and loss of mobility. </p>
<p>How can osteoporosis be treated? 
As well as your treatment with VANTAVO, your doctor may suggest you make changes to your 
lifestyle to help your condition, such as: </p>
<p>Stopping smoking 
Smoking appears to increase the rate at which you lose bone and, therefore, 
may increase your risk of broken bones. </p>
<p>Exercise 
Like muscles, bones need exercise to stay strong and healthy. Consult your 
doctor before you begin any exercise programme. </p>
<p>Eating a balanced diet Your doctor can advise you about your diet or whether you should take any 
dietary supplements. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vantavo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vantavo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take VANTAVO 
* if you are allergic to alendronic acid, colecalciferol or any of the other ingredients of this 
medicine (listed in section 6), 
* if you have certain problems with your gullet (oesophagus - the tube that connects your mouth 
with your stomach) such as narrowing or difficulty swallowing,<br />
* if you cannot stand or sit upright for at least 30 minutes, 
* if your doctor has told you that you have low blood calcium. </p>
<p>If you think any of these apply to you, do not take the tablets. Talk to your doctor first and follow the 
advice given. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking VANTAVO if:<br />
<em> you suffer from kidney problems, 
* you have, or have recently had, any swallowing or digestive problems, 
* your doctor has told you that you have Barrett's oesophagus (a condition associated with 
changes in the cells that line the lower oesophagus), 
* have been told you have trouble absorbing minerals in your stomach or intestines 
(malabsorption syndrome), 
* you have poor dental health, gum disease, a planned dental extraction or you don t receive 
routine dental care,<br />
</em> you have cancer, 
* you are undergoing chemotherapy or radiotherapy, 
* you are taking angiogenesis inhibitors (such as bevacizumab, or thalidomide) which are used in 
the treatment of cancer, 
* you are taking corticosteroids (such as prednisone or dexamethasone) which are used in the 
treatment of such conditions as asthma, rheumatoid arthritis, and severe allergies, 
* you are or have been a smoker (as this may increase the risk of dental problems). </p>
<p>You may be advised to have a dental check-up before starting treatment with VANTAVO. </p>
<p>It is important to maintain good oral hygiene when being treated with VANTAVO. You should have 
routine dental check-ups throughout your treatment and you should contact your doctor or dentist if 
you experience any problems with your mouth or teeth such as loose teeth, pain or swelling. </p>
<p>Irritation, inflammation or ulceration of the gullet (oesophagus   the tube that connects your mouth 
with your stomach) often with symptoms of chest pain, heartburn, or difficulty or pain upon 
swallowing may occur, especially if patients do not drink a full glass of water and/or if they lie down 
less than 30 minutes after taking VANTAVO. These side effects may worsen if patients continue to 
take VANTAVO after developing these symptoms. </p>
<p>Children and adolescents<br />
VANTAVO should not be given to children and adolescents less than 18 years of age. </p>
<p>Other medicines and VANTAVO 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>It is likely that calcium supplements, antacids, and some oral medicines will interfere with the 
absorption of VANTAVO if taken at the same time. Therefore, it is important that you follow the 
advice given in section 3 and wait at least 30 minutes before taking any other oral medicines or 
supplements. </p>
<p>Certain medicines for rheumatism or long-term pain called NSAIDs (e.g. acetylsalicylic acid or 
ibuprofen) might cause digestive problems. Therefore, caution should be used when these medicines 
are taken at the same time as VANTAVO. </p>
<p>It is likely that certain medicines or food additives may prevent the vitamin D in VANTAVO from 
getting into your body, including artificial fat substitutes, mineral oils, the weight loss medicine, 
orlistat, and the cholesterol-lowering medicines, cholestyramine and colestipol. Medicines for fits 
(seizures) (like phenytoin or phenobarbital) may decrease the effectiveness of vitamin D. Additional 
vitamin D supplements may be considered on an individual basis. </p>
<p>VANTAVO with food and drink 
It is likely that food and beverages (including mineral water) will make VANTAVO less effective if 
taken at the same time. Therefore, it is important that you follow the advice given in section 3. You 
must wait at least 30 minutes before taking any food and beverages except water. </p>
<p>Pregnancy and breast-feeding 
VANTAVO is only intended for use in postmenopausal women. You should not take VANTAVO if 
you are or think you may be pregnant, or if you are breast-feeding. </p>
<p>Driving and using machines 
There have been side effects (for example, blurred vision, dizziness and severe bone, muscle or joint 
pain) reported with VANTAVO that may affect your ability to drive or operate machinery (see section 
4). If you experience any of these side effects you should not drive until you feel better. </p>
<p>VANTAVO contains lactose and sucrose. 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>
<p>VANTAVO contains sodium.<br />
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vantavo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vantavo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take VANTAVO exactly as your doctor or pharmacist has told you. Check with your doctor or 
pharmacist if you are not sure. </p>
<p>Take one VANTAVO tablet once a week. </p>
<p>Follow these instructions carefully. </p>
<p>1) 
Choose the day of the week that best fits your schedule. Every week, take one VANTAVO 
tablet on your chosen day. </p>
<p>It is very important to follow instructions 2), 3), 4) and 5) to help the VANTAVO tablet reach your 
stomach quickly and help reduce the chance of irritating your gullet (oesophagus - the tube that 
connects your mouth with your stomach). </p>
<p>2) 
After getting up for the day and before taking any food, drink, or other medicine, swallow your 
VANTAVO tablet whole with a full glass of water only (not mineral water) (not less than 
200 ml), so that VANTAVO is adequately absorbed. 
* Do not take with mineral water (still or sparkling). 
* Do not take with coffee or tea. 
* Do not take with juice or milk. </p>
<p>Do not crush or chew the tablet or allow it to dissolve in your mouth because of the possibility of 
mouth ulceration. </p>
<p>3) 
Do not lie down   stay fully upright (sitting, standing or walking)   for at least 30 minutes 
after swallowing the tablet. Do not lie down until after your first food of the day. </p>
<p>4) 
Do not take VANTAVO at bedtime or before getting up for the day. </p>
<p>5) 
If you develop difficulty or pain upon swallowing, chest pain, or new or worsening heartburn, 
stop taking VANTAVO and contact your doctor. </p>
<p>6) 
After swallowing your VANTAVO tablet, wait at least 30 minutes before taking your first food, 
drink, or other medicine of the day, including antacids, calcium supplements and vitamins. 
VANTAVO is effective only if taken when your stomach is empty. </p>
<p>If you take more VANTAVO than you should 
If you take too many tablets by mistake, drink a full glass of milk and contact your doctor 
immediately. Do not make yourself vomit, and do not lie down. </p>
<p>If you forget to take VANTAVO 
If you miss a dose, just take one tablet on the morning after you remember. Do not take two tablets on 
the same day. Return to taking one tablet once a week, as originally scheduled on your chosen day. </p>
<p>If you stop taking VANTAVO 
It is important that you take VANTAVO for as long as your doctor prescribes the medicine. Since it is 
not known how long you should take VANTAVO, you should discuss the need to stay on this 
medicine with your doctor periodically to determine if VANTAVO is still right for you. </p>
<p>An Instruction Card is included in the carton for VANTAVO. It contains important information 
reminding you how to take VANTAVO properly. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>See your doctor immediately if you notice any of the following side effects, which may be serious, 
and for which you may need urgent medical treatment: 
Common (may affect up to 1 in 10 people):<br />
* heartburn; difficulty swallowing; pain upon swallowing; ulceration of the gullet (oesophagus - the tube that connects your mouth with your stomach) which can cause chest pain, heartburn or 
difficulty or pain upon swallowing.  </p>
<p>Rare (may affect up to 1 in 1,000 people): 
* allergic reactions such as hives; swelling of the face, lips, tongue and/or throat, possibly causing 
difficulty breathing or swallowing; severe skin reactions, 
* pain in the mouth, and/or jaw, swelling or sores inside the mouth, numbness or a feeling of 
heaviness in the jaw, or loosening of a tooth. These could be signs of bone damage in the jaw 
(osteonecrosis) generally associated with delayed healing and infection, often following tooth 
extraction. Contact your doctor and dentist if you experience such symptoms,<br />
<em> unusual fracture of the thigh bone particularly in patients on long-term treatment for 
osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or 
discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of 
the thigh bone,<br />
</em> bone, muscle and/or joint pain which is severe. </p>
<p>Not known (cannot be estimated from the available data): 
* unusual fracture in locations other than thigh bone. </p>
<p>Other side effects include 
Very common (may affect more than 1 in 10 people): 
* bone, muscle and/or joint pain which is sometimes severe. </p>
<p>Common (may affect up to 1 in 10 people):<br />
<em> joint swelling, 
* abdominal pain; uncomfortable feeling in the stomach or belching after eating; constipation; full 
or bloated feeling in the stomach; diarrhoea; flatulence,<br />
</em> hair loss; itching, 
* headache; dizziness, 
* tiredness; swelling in the hands or legs. </p>
<p>Uncommon (may affect up to 1 in 100 people):<br />
<em> nausea; vomiting,<br />
</em> irritation or inflammation of the gullet (oesophagus   the tube that connects your mouth with 
your stomach) or stomach,<br />
<em> black or tar-like stools,<br />
</em> blurred vision; pain or redness in the eye, 
* rash; redness of the skin, 
* transient flu-like symptoms, such as aching muscles, generally feeling unwell and sometimes 
with fever usually at the start of treatment, 
* taste disturbance.  </p>
<p>Rare (may affect up to 1 in 1,000 people):<br />
<em> symptoms of low blood calcium levels including muscle cramps or spasms and/or tingling 
sensation in the fingers or around the mouth,<br />
</em> stomach or peptic ulcers (sometimes severe or with bleeding),<br />
<em> narrowing of the gullet (oesophagus   the tube that connects your mouth with your stomach),<br />
</em> rash made worse by sunlight, 
* mouth ulcers. 
Very rare (may affect up to 1 in 10,000 people): 
* talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. These 
could be signs of bone damage in the ear. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vantavo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vantavo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Store in the original blister in order to protect from moisture and light. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What VANTAVO contains </p>
<p>The active substances are alendronic acid and colecalciferol (vitamin D3). Each VANTAVO 
70 mg/2,800 IU tablet contains 70 mg alendronic acid (as sodium trihydrate) and 70 micrograms 
(2800 IU) colecalciferol (vitamin D3). Each VANTAVO 70 mg/5,600 IU tablet contains 70 mg 
alendronic acid (as sodium trihydrate) and 140 micrograms (5,600 IU) colecalciferol (vitamin D3). </p>
<p>The other ingredients are microcrystalline cellulose (E460), lactose anhydrous (see section 2), medium 
chain triglycerides, gelatin, croscarmellose sodium, sucrose (see section 2), colloidal silicon dioxide, 
magnesium stearate (E572), butyl hydroxytoluene (E321), modified starch (maize), and sodium 
aluminium silicate (E554). </p>
<p>What VANTAVO looks like and contents of the pack </p>
<p>VANTAVO 70 mg/2800 IU tablets are available as modified capsule-shaped, white to off-white 
tablets marked with an outline of a bone image on one side and  710  on the other. VANTAVO 
70 mg/2,800 IU tablets are available in packs containing 2, 4, 6 or 12 tablets. </p>
<p>VANTAVO 70 mg/5,600 IU tablets are available as modified rectangle-shaped, white to off-white 
tablets marked with an outline of a bone image on one side and  270  on the other. VANTAVO 
70 mg/5,600 IU tablets are available in packs containing 2, 4 or 12 tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
N.V. Organon 
Kloosterstraat 6 
5349 AB Oss 
The Netherlands 
Manufacturer 
Merck Sharp &amp; Dohme B.V. 
Waarderweg 2031 BN Haarlem 
The Netherlands </p>
<p>Organon Heist bv<br />
Industriepark 2220 Heist-op-den-Berg<br />
Belgium </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. </p>
<p>Belgi /Belgique/Belgien 
Organon Belgium 
T l/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Lietuva 
Organon Pharma B.V. Lithuania atstovyb<br />
Tel.: +370 52041dpoc.lithuania@organon.com </p>
<p>( . .)  . . -   <br />
 .: +359 2 806 3dpoc.bulgaria@organon.com </p>
<p>Luxembourg/Luxemburg<br />
Organon Belgium 
T l/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>esk  republika 
Organon Czech Republic s.r.o. 
Tel: +420 233 010 dpoc.czech@organon.com </p>
<p>Magyarorsz g 
Organon Hungary Kft. 
Tel.: +36 1 766 1dpoc.hungary@organon.com </p>
<p>Danmark 
Organon Denmark ApS<br />
Tlf: +45 4484 6info.denmark@organon.com </p>
<p>Malta 
Organon Pharma B.V., Cyprus branch 
Tel: +356 2277 8dpoc.cyprus@organon.com </p>
<p>Deutschland 
Organon Healthcare GmbH 
Tel: 0800 3384 726 (+49 (0) 89 2040022 10) 
dpoc.germany@organon.com </p>
<p>Nederland 
N.V. Organon 
Tel.: 00800 66550123 (+32 2 2418100) 
dpoc.benelux@organon.com </p>
<p>Eesti 
Organon Pharma B.V. Estonian RO 
Tel: +372 66 61 dpoc.estonia@organon.com </p>
<p>Norge 
Organon Norway AS 
Tlf: +47 24 14 56 info.norway@organon.com </p>
<p>E<br />
N.V. Organon 
 : + 30-216 6008 sterreich 
Organon Healthcare GmbH<br />
Tel: +49 (0) 89 2040022 dpoc.austria@organon.com 
Espa a 
Organon Salud, S.L. 
Tel: +34 91 591 12 organon_info@organon.com </p>
<p>Polska 
Organon Polska Sp. z o.o. 
Tel.: +48 22 105 50 organonpolska@organon.com </p>
<p>France 
Organon France<br />
T l: +33 (0) 1 57 77 32 Portugal 
Organon Portugal, Sociedade Unipessoal Lda. 
Tel: +351 218705geral_pt@organon.com </p>
<p>Hrvatska 
Organon Pharma d.o.o. 
Tel: +385 1 638 4dpoc.croatia@organon.com </p>
<p>Rom nia 
Organon Biosciences S.R.L. 
Tel: +40 21 527 29 dpoc.romania@organon.com<br />
Ireland 
Organon Pharma (Ireland) Limited 
Tel: +353 15828medinfo.ROI@organon.com </p>
<p>Slovenija 
Organon Pharma B.V., Oss, podru nica Ljubljana 
Tel: +386 1 300 10 dpoc.slovenia@organon.com 
 sland 
Vistor hf. 
S mi: +354 535 7Slovensk  republika 
Organon Slovakia s. r. o. 
Tel: +421 2 44 88 98 dpoc.slovakia@organon.com </p>
<p>talia 
Neopharmed Gentili S.p.A. 
Tel. + 39 02 89 13 regulatory@neogen.it </p>
<p>Suomi/Finland 
Organon Finland Oy 
Puh/Tel: +358 (0) 29 170 3dpoc.finland@organon.com </p>
<p>Organon Pharma B.V., Cyprus branch 
 : +357 22866dpoc.cyprus@organon.com </p>
<p>Sverige 
Organon Sweden AB 
Tel: +46 8 502 597 dpoc.sweden@organon.com </p>
<p>Latvija 
 rvalsts komersanta  Organon Pharma B.V.<br />
p rst vniec ba 
Tel: +371 66968dpoc.latvia@organon.com </p>
<p>United Kingdom (Northern Ireland) 
Organon Pharma (UK) Limited<br />
Tel: +44 (0) 208 159 3medicalinformationuk@organon.com  </p>
<p>This leaflet was last revised in &lt;{MM/YYYY}&gt;. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency website: 
https://www.ema.europa.eu. </p>         </div>"""      



Instance: composition-da-bbd22ba876ae7309a2b1061a1e9bb063
InstanceOf: CompositionUvEpi
Title: "Composition for vantavo Package Leaflet"
Description:  "Composition for vantavo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/09/572/001 – 2 tablets"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpbbd22ba876ae7309a2b1061a1e9bb063)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vantavo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage VANTAVO 
3. Sådan skal du tage VANTAVO 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vantavo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vantavo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad er VANTAVO? 
VANTAVO er en tablet, der indeholder to aktive stoffer, alendronsyre (kaldes normalt alendronat) og 
cholecalciferol, kendt som D3-vitamin. </p>
<p>Hvad er alendronat? 
Alendronat tilhører en gruppe ikke-hormonelle lægemidler, som kaldes bisphosphonater. Alendronat 
hindrer det knogletab, der opstår hos kvinder efter overgangsalderen og bidrager til at genopbygge 
knoglemassen. Alendronat nedsætter risikoen for hoftebrud samt brud på rygsøjlen.  </p>
<p>Hvad er D-vitamin? 
D-vitamin er et vigtigt næringsstof, som er nødvendigt for kalkoptagelsen og sunde knogler. Kroppen 
kan kun optage kalk ordentligt fra maden, hvis der er nok D-vitamin til stede. Meget få fødevarer 
indeholder D-vitamin. Den væsentligste kilde er sommerens sollys, som danner D-vitamin i vores hud. 
Efterhånden som vi bliver ældre, danner vores hud mindre D-vitamin. For lidt D-vitamin kan føre til 
knogletab og knogleskørhed. Alvorlig D-vitaminmangel kan forårsage muskelsvaghed, som kan føre 
til fald og større risiko for knoglebrud. </p>
<p>Hvad anvendes VANTAVO til? 
Din læge har ordineret VANTAVO til at behandle din knogleskørhed, og fordi du er i risiko for D-
vitaminmangel. Det nedsætter risikoen for hoftebrud og brud på rygsøjlen hos kvinder efter 
overgangsalderen. </p>
<p>Hvad er knogleskørhed? 
Knogleskørhed medfører tyndere og svagere knogler og er almindeligt hos kvinder efter 
overgangsalderen. Når menstruationerne ophører, holder æggestokkene op med at producere det 
kvindelige kønshormon østrogen, som medvirker til at holde kvindens knogler sunde. Som resultat 
opstår knogletab, og knoglerne bliver svagere. Jo tidligere en kvinde når overgangsalderen, jo større er 
risikoen for knogleskørhed. </p>
<p>Tidligt i forløbet har knogleskørhed som regel ingen symptomer. Men hvis det ikke bliver behandlet, 
kan det resultere i knoglebrud. Selvom knoglebrud sædvanligvis gør ondt, kan knoglebrud i rygsøjlen 
forblive ubemærket, indtil patienten får sammenfald i ryggen. Knoglebrud kan opstå under normale 
daglige aktiviteter, såsom løft eller som følge af mindre skader, som ikke sædvanligvis bevirker brud 
på normale knogler. Knoglebrud opstår som regel i hoften, rygsøjlen eller håndleddet og kan medføre 
ikke kun smerte, men også betydelige problemer såsom foroverbøjet stilling (pukkelryg) og tab af 
bevægelighed. </p>
<p>Hvordan kan knogleskørhed behandles? 
Såvel som behandling med VANTAVO kan din læge foreslå, at du foretager nogle ændringer i din 
livsstil, som kan hjælpe dig i din tilstand, for eksempel: </p>
<p>Rygestop </p>
<p>Rygning synes at øge hastigheden for knogletabet og kan derfor øge </p>
<p>risikoen for knoglebrud. </p>
<p>Motion  </p>
<p>Ligesom musklerne har knoglerne brug for motion for at forblive stærke og  </p>
<p>sunde. Kontakt din læge før du begynder på et træningsprogram. </p>
<p>Afbalanceret kost 
Din læge kan rådgive dig om kosten eller om, hvorvidt du bør tage  </p>
<p>kosttilskud. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vantavo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vantavo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke VANTAVO </p>
<ul>
<li>
<p>hvis du er allergisk over for alendronsyre, cholecalciferol eller et af de øvrige indholdsstoffer i 
VANTAVO (angivet i punkt 6), </p>
</li>
<li>
<p>hvis du har visse problemer med spiserøret (øsofagus - det rør der forbinder din mund med 
maven), såsom forsnævring eller synkebesvær, </p>
</li>
<li>
<p>hvis du ikke er i stand til at stå eller sidde oprejst i mindst 30 minutter, </p>
</li>
<li>
<p>hvis din læge har fortalt dig, at dit kalkindhold i blodet er lavt. </p>
</li>
</ul>
<p>Tag ikke tabletterne, hvis du mener, at noget af ovenstående passer på dig. Tal med din læge og følg 
lægens råd. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager VANTAVO hvis: </p>
<ul>
<li>
<p>Du har nyreproblemer, </p>
</li>
<li>
<p>Du har eller for nylig har haft synkebesvær eller fordøjelsesproblemer, </p>
</li>
<li>
<p>Din læge har fortalt dig, at du har Barretts øsofagus (en tilstand med celleforandringer i nederste 
del af spiserøret), </p>
</li>
<li>
<p>Du har fået at vide, at du har svært ved at optage mineraler i maven eller tarmen 
(malabsorptionssyndrom), </p>
</li>
<li>
<p>Du har dårlig mundhygiejne, tandkødslidelser, planlagt tandudtrækning, eller hvis du ikke får 
regelmæssig tandpleje, </p>
</li>
<li>
<p>Du har kræft, </p>
</li>
<li>
<p>Du får kemoterapi eller strålebehandling, </p>
</li>
<li>
<p>Du tager angiogenesehæmmere (hæmmer nydannelse af blod- og lymfekar) (f.eks. bevacizumab 
eller thalidomid), som anvendes ved behandling af cancer, </p>
</li>
<li>
<p>Du tager kortikosteroider (f.eks. prednison eller dexamethason), som anvendes ved behandling 
af visse sygdomme såsom astma, reumatoid artrit og svære allergier, </p>
</li>
<li>
<p>Du er eller har været ryger (da det kan øge risikoen for tandproblemer). </p>
</li>
</ul>
<p>Du kan blive rådet til et tandlægebesøg, før du begynder behandling med VANTAVO. </p>
<p>Det er vigtigt at opretholde en god mundhygiejne, når du er i behandling med VANTAVO. Du bør gå 
regelmæssigt til tandlægen under din behandling, og du skal kontakte din læge eller tandlæge, hvis du 
oplever problemer med din mund eller tænder såsom løse tænder, smerter eller hævelser.  </p>
<p>Irritation, betændelse eller sårdannelse i spiserøret (øsofagus - det rør der forbinder din mund med 
maven), ofte med symptomer så som brystsmerter, halsbrand, synkebesvær eller synkesmerter opstår 
især, hvis patienten ikke drikker et helt glas vand, og/eller hvis man lægger sig ned inden 30 minutter, 
efter man har taget VANTAVO. Disse bivirkninger kan forværres, hvis patienten fortsætter med at 
tage VANTAVO efter at have udviklet sådanne symptomer. </p>
<p>Børn og unge 
VANTAVO bør ikke gives til børn og unge under 18 år. </p>
<p>Brug af anden medicin sammen med VANTAVO 
Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger anden medicin, for nylig har brugt 
anden medicin eller planlægger at brugen anden medicin.  </p>
<p>Det er sandsynligt, at kalktilskud, syreneutraliserende midler og nogle andre former for medicin, der 
tages gennem munden, vil påvirke kroppens optagelse af VANTAVO, hvis det tages samtidigt. Det er 
derfor vigtigt, at du følger instruktionen i punkt 3 og venter 30 minutter, før du tager anden medicin 
eller tilskud. </p>
<p>Visse lægemidler mod gigt eller langvarige smerter, NSAID (f.eks. acetylsalicylsyre eller ibuprofen) 
kan medføre fordøjelsesproblemer. Derfor bør der udvises forsigtighed, når disse lægemidler tages 
samtidigt med VANTAVO.  </p>
<p>Det er sandsynligt, at visse lægemidler eller tilsætningsstoffer i maden kan forhindre optagelsen af D-
vitaminet i VANTAVO i kroppen. Disse omfatter kunstige fedterstatninger, mineralske olier, 
slankemidlet orlistat og de kolesterolsænkende lægemidler colestyramin og colestipol. Medicin til 
krampeanfald (såsom phenytoin eller phenobarbital) kan nedsætte virkningen af D-vitamin. Yderligere 
D-vitamintilskud kan overvejes for den enkelte patient. </p>
<p>Brug af VANTAVO sammen med mad og drikke 
Det er sandsynligt, at mad og drikke (også mineralvand) vil nedsætte virkningen af VANTAVO, hvis 
det indtages på samme tid. Det er derfor vigtigt, at du følger instruktionen i punkt 3. Du skal vente 
mindst 30 minutter, før du indtager mad eller drikke, med undtagelse af vand. </p>
<p>Graviditet og amning 
VANTAVO er kun beregnet til kvinder efter overgangsalderen. Tag ikke VANTAVO, hvis du er 
gravid, tror du kan være gravid eller hvis du ammer. </p>
<p>Trafik- og arbejdssikkerhed 
Der er set bivirkninger med VANTAVO (f.eks. sløret syn, svimmelhed og alvorlige knogle-, muskel- eller ledsmerter), som kan påvirke evnen til at køre bil eller betjene maskiner (se punkt 4). Hvis du får 
nogle af disse bivirkninger, må du ikke køre bil, før du får det bedre. </p>
<p>VANTAVO indeholder lactose og saccharose. 
Hvis din læge har fortalt, at der er nogle sukkerarter, du ikke kan tåle, skal du kontakte lægen, før du 
tager denne medicin. </p>
<p>VANTAVO indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vantavo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vantavo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet.  </p>
<p>Tag én VANTAVO tablet én gang ugentligt. </p>
<p>Følg disse instruktioner nøje. </p>
<ol>
<li>Vælg den ugedag, der passer dig bedst. Tag én VANTAVO tablet hver uge på den valgte ugedag. </li>
</ol>
<p>Det er meget vigtigt, at du følger instruktionerne 2), 3), 4) og -5) for at VANTAVO-tabletten hurtigt 
kan komme ned i maven og for at nedsætte risikoen for irritation af spiserøret (øsofagus - det rør der 
forbinder din mund med maven). </p>
<ol>
<li>
<p>Slug VANTAVO tabletten hel med et helt glas postevand (ikke mineralvand), mindst 200 ml, så 
VANTAVO kan blive ordentligt optaget, efter du er stået op, og før du indtager mad, drikke eller 
anden medicin. </p>
</li>
<li>
<p>Tag ikke tabletten med mineralvand. </p>
</li>
<li>
<p>Tag ikke tabletten med kaffe eller te. </p>
</li>
<li>
<p>Tag ikke tabletten med juice eller mælk. </p>
</li>
</ol>
<p>Du må ikke knuse eller tygge tabletten eller lade den blive opløst i munden på grund af risikoen for sår 
i munden. </p>
<ol>
<li>Når du har slugt VANTAVO tabletten, må du ikke lægge dig ned - du skal forblive  </li>
</ol>
<p>oprejst (siddende, stående eller gående) i mindst 30 minutter. Du må ikke lægge dig ned,  </p>
<p>før du har indtaget dagens første måltid. </p>
<ol>
<li>
<p>Tag ikke VANTAVO ved sengetid, eller før du står op. </p>
</li>
<li>
<p>Hvis du udvikler synkebesvær, synkesmerter, brystsmerter eller ny/forværret halsbrand,  </p>
</li>
</ol>
<p>skal du stoppe med at tage VANTAVO og kontakte din læge. </p>
<ol>
<li>Når du har slugt VANTAVO tabletten, skal du vente mindst 30 minutter, før du indtager<br />
dagens første måltid, drikke eller anden medicin, også syreneutraliserende midler, kalktilskud og 
vitaminer. VANTAVO er kun effektivt, hvis det tages på tom mave. </li>
</ol>
<p>Hvis du har taget for meget VANTAVO<br />
Hvis du ved en fejltagelse kommer til at tage for mange tabletter, skal du drikke et helt glas mælk og 
straks kontakte din læge. Fremkald ikke opkastning og læg dig ikke ned. </p>
<p>Hvis du har glemt at tage VANTAVO 
Hvis du glemmer at tage en tablet, skal du blot tage en VANTAVO tablet om morgenen, efter du er 
kommet i tanke om det. Tag ikke to tabletter på samme dag. Fortsæt med at tage én tablet om ugen, på 
den ugedag, du oprindeligt har valgt. </p>
<p>Hvis du holder op med at tage VANTAVO 
Det er vigtigt, at du tager VANTAVO, så længe din læge foreskriver medicinen. Da det er ukendt, 
hvor lang tid du skal tage VANTAVO, skal du med jævne mellemrum diskutere behovet for at 
fortsætte med dette lægemiddel med din læge for at afgøre, om VANTAVO stadig er rigtigt for dig.  </p>
<p>Der er vedlagt et instruktionskort i VANTAVO pakningen. Det angiver vigtig information, som vil 
minde dig om, hvordan du skal tage VANTAVO korrekt. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.  </p>
<p>Kontakt straks lægen, hvis du bemærker en eller flere af følgende bivirkninger, som kan være 
alvorlige, og som kan kræve akut lægehjælp: 
Almindelige (kan berøre op til 1 person ud af 10): </p>
<ul>
<li>Halsbrand, synkebesvær, synkesmerter, sårdannelse i spiserøret (øsofagus - det rør der forbinder 
din mund med maven), som kan medføre smerter i brystet, halsbrand eller 
synkebesvær/synkesmerter. </li>
</ul>
<p>Sjældne (kan berøre op til 1 person ud af 1 000): </p>
<ul>
<li>
<p>Allergiske reaktioner som nældefeber; hævelse af ansigt, læber, tunge og/eller svælg, som 
muligvis kan medføre vejrtræknings- og synkebesvær; svære hudreaktioner. </p>
</li>
<li>
<p>Smerter i munden og/eller kæben, hævelser eller sår inde i munden, følelsesløshed eller 
tyngdefornemmelse i kæben eller løse tænder. Dette kan være tegn på knogleskade i kæben 
(knoglenekrose), der generelt er forbundet med forsinket sårheling og infektion, ofte efter 
tandudtrækning. Kontakt din læge eller tandlæge, hvis du oplever disse symptomer.  </p>
</li>
<li>
<p>Usædvanlige brud på lårbensknoglen, primært hos patienter i langtidsbehandling for 
knogleskørhed, kan forekomme i sjældne tilfælde. Kontakt lægen hvis du får smerter, svaghed 
eller ubehag i låret, hoften eller lysken, idet det kan være tidlige tegn på et muligt brud på 
lårbensknoglen. </p>
</li>
<li>
<p>Svære knogle- muskel- og/eller ledsmerter. </p>
</li>
</ul>
<p>Ikke kendt (kan ikke estimeres ud fra forhåndenværende data): </p>
<ul>
<li>Usædvanlige brud andre steder end på lårbensknoglen. </li>
</ul>
<p>Andre bivirkninger 
Meget almindelige (kan berøre mere end 1 person ud af 10):  </p>
<ul>
<li>Knogle- muskel- og/eller ledsmerter, som kan være voldsomme.  </li>
</ul>
<p>Almindelige (kan berøre op til 1 person ud af 10): </p>
<ul>
<li>
<p>Ledhævelse </p>
</li>
<li>
<p>Mavesmerter, ubehagsfølelse i maven eller opstød efter at have spist, forstoppelse, oppustet 
mave, diarré, øget luftafgang fra tarmen. </p>
</li>
<li>
<p>Hårtab, kløe. </p>
</li>
<li>
<p>Hovedpine, svimmelhed. </p>
</li>
<li>
<p>Træthed, hævede hænder eller ben. </p>
</li>
</ul>
<p>Ikke almindelige (kan berøre op til 1 person ud af 100): </p>
<ul>
<li>
<p>Kvalme, opkastning. </p>
</li>
<li>
<p>Irritation eller betændelse i spiserøret (øsofagus - det rør der forbinder din mund med maven) 
eller i maven. </p>
</li>
<li>
<p>Sort eller tjærelignende afføring. </p>
</li>
<li>
<p>Sløret syn, smerte eller rødmen i øjet. </p>
</li>
<li>
<p>Udslæt, rødmen af hud. </p>
</li>
<li>
<p>Forbigående influenzalignende symptomer som for eksempel ømme muskler, generel 
utilpashed og nogle gange feber, sædvanligvis i starten af behandlingen. </p>
</li>
<li>
<p>Smagsforstyrrelser. </p>
</li>
</ul>
<p>Sjældne (kan berøre op til 1 person ud af 1 000): </p>
<ul>
<li>
<p>Symptomer på for lavt indhold af kalk i blodet omfattende muskelkramper eller trækninger 
og/eller prikkende fornemmelse i fingrene eller omkring munden.  </p>
</li>
<li>
<p>Mavesår eller sår i mave- og tarmkanalen (nogle gange alvorlige eller med blødning). </p>
</li>
<li>
<p>Indsnævring af spiserøret (øsofagus - det rør der forbinder din mund med maven). </p>
</li>
<li>
<p>Udslæt forværret af sollys. </p>
</li>
<li>
<p>Sår i munden. </p>
</li>
</ul>
<p>Meget sjældne (kan berøre op til 1 person ud af 10 000):  </p>
<ul>
<li>Sig det til lægen, hvis du får øresmerter, udflåd fra øret og/eller betændelse i øret. Dette kan 
være tegn på knoglebeskadigelse i øret. </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Sundhedsstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vantavo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vantavo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakning og blister. Udløbsdatoen er den sidste 
dag i den nævnte måned. </p>
<p>Opbevar lægemidlet i den originale blisterpakning for at beskytte mod fugt og lys. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>VANTAVO indeholder: </p>
<p>Aktive stoffer: Alendronsyre og cholecalciferol (D3-vitamin). Hver VANTAVO 70 mg/2.800 IE tablet<br />
indeholder 70 mg alendronsyre (som natriumtrihydrat) og 70 mikrogram (2.800 IE) 
cholecalciferol (D3-vitamin). Hver VANTAVO 70 mg/5.600 IE tablet indeholder 70 mg alendronsyre 
(som natriumtrihydrat) og 140 mikrogram (5.600 IE) cholecalciferol (D3-vitamin). </p>
<p>Øvrige indholdsstoffer: Mikrokrystallinsk cellulose (E460); lactose, vandfri (se punkt 2); triglycerider 
middelkædelængde; gelatine; croscarmellosenatrium; saccharose (se punkt 2); silica, kolloid vandfri; 
magnesiumstearat (E572); butyl hydroxytoluen (E321); modificeret majsstivelse og 
natriumaluminiumsilicat (E554). </p>
<p>Udseende og pakningsstørrelser </p>
<p>VANTAVO 70 mg/2.800 IE tabletter er modificeret kapselformede hvide/beige tabletter mærket med 
omridset af en knogle på den ene side og "710" på den anden side. VANTAVO 70 mg/2.800 IE 
tabletter fås i pakninger med 2, 4, 6 eller 12 tabletter. </p>
<p>VANTAVO 70 mg/5.600 IE tabletter er modificeret rektangulære, hvide/beige tabletter, der er mærket 
med omridset af en knogle på den ene side og "270" på den anden side. VANTAVO 70 mg/5.600 IE 
tabletter fås i pakninger med 2, 4 eller 12 tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
N.V. Organon 
Kloosterstraat 6 
5349 AB Oss 
Fremstiller 
Merck Sharp &amp; Dohme B.V. 
Waarderweg 2031 BN Haarlem 
Holland 
Holland </p>
<p>Organon Heist bv<br />
Industriepark 30<br />
2220 Heist-op-den-Berg<br />
Belgien </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:  </p>
<p>België/Belgique/Belgien 
Organon Belgium 
Tél/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Lietuva 
Organon Pharma B.V. Lithuania atstovybė 
Tel.: +370 52041dpoc.lithuania@organon.com </p>
<p>България 
Органон (И.А.) Б.В. - клон България 
Тел.: +359 2 806 3dpoc.bulgaria@organon.com </p>
<p>Luxembourg/Luxemburg<br />
Organon Belgium 
Tél/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Česká republika 
Organon Czech Republic s.r.o. 
Tel: +420 233 010 dpoc.czech@organon.com </p>
<p>Magyarország 
Organon Hungary Kft. 
Tel.: +36 1 766 1dpoc.hungary@organon.com </p>
<p>Danmark 
Organon Denmark ApS<br />
Tlf: +45 4484 6info.denmark@organon.com </p>
<p>Malta 
Organon Pharma B.V., Cyprus branch 
Tel: +356 2277 8dpoc.cyprus@organon.com </p>
<p>Deutschland 
Organon Healthcare GmbH 
Tel: 0800 3384 726 (+49 (0) 89 2040022 10) 
dpoc.germany@organon.com </p>
<p>Nederland 
N.V. Organon 
Tel.: 00800 66550123 (+32 2 2418100) 
dpoc.benelux@organon.com </p>
<p>Eesti 
Organon Pharma B.V. Estonian RO 
Tel: +372 66 61 dpoc.estonia@organon.com </p>
<p>Norge 
Organon Norway AS 
Tlf: +47 24 14 56 info.norway@organon.com </p>
<p>Eλλάδα 
N.V. Organon 
Τηλ: + 30-216 6008 
Österreich 
Organon Healthcare GmbH<br />
Tel: +49 (0) 89 2040022 dpoc.austria@organon.com 
España 
Organon Salud, S.L. 
Tel: +34 91 591 12 organon_info@organon.com </p>
<p>Polska 
Organon Polska Sp. z o.o. 
Tel.: +48 22 105 50 organonpolska@organon.com </p>
<p>France 
Organon France<br />
Tél: +33 (0) 1 57 77 32<br />
Portugal 
Organon Portugal, Sociedade Unipessoal Lda. 
Tel: +351 218705geral_pt@organon.com </p>
<p>Hrvatska 
Organon Pharma d.o.o. 
Tel: +385 1 638 4dpoc.croatia@organon.com </p>
<p>România 
Organon Biosciences S.R.L. 
Tel: +40 21 527 29 dpoc.romania@organon.com<br />
Ireland 
Organon Pharma (Ireland) Limited 
Tel: +353 15828medinfo.ROI@organon.com </p>
<p>Slovenija 
Organon Pharma B.V., Oss, podružnica Ljubljana 
Tel: +386 1 300 10 dpoc.slovenia@organon.com 
Ísland 
Vistor hf. 
Sími: +354 535 7 
Slovenská republika 
Organon Slovakia s. r. o. 
Tel: +421 2 44 88 98 dpoc.slovakia@organon.com </p>
<p>Ιtalia 
Neopharmed Gentili S.p.A. 
Tel. + 39 02 89 13 regulatory@neogen.it </p>
<p>Suomi/Finland 
Organon Finland Oy 
Puh/Tel: +358 (0) 29 170 3dpoc.finland@organon.com </p>
<p>Κύπρος 
Organon Pharma B.V., Cyprus branch 
Τηλ: +357 22866dpoc.cyprus@organon.com </p>
<p>Sverige 
Organon Sweden AB 
Tel: +46 8 502 597 dpoc.sweden@organon.com </p>
<p>Latvija 
Ārvalsts komersanta “Organon Pharma B.V." 
pārstāvniecība 
Tel: +371 66968dpoc.latvia@organon.com </p>
<p>United Kingdom (Northern Ireland) 
Organon Pharma (UK) Limited<br />
Tel: +44 (0) 208 159 3593<br />
medicalinformationuk@organon.com  </p>
<p>Denne indlægsseddel blev senest ændret &lt;{MM/YYYY}&gt; </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-bbd22ba876ae7309a2b1061a1e9bb063
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vantavo Package Leaflet for language en"
Description: "ePI document Bundle for vantavo Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-bbd22ba876ae7309a2b1061a1e9bb063"
* entry[0].resource = composition-en-bbd22ba876ae7309a2b1061a1e9bb063

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpbbd22ba876ae7309a2b1061a1e9bb063"
* entry[=].resource = mpbbd22ba876ae7309a2b1061a1e9bb063
                            
                    
Instance: bundlepackageleaflet-da-bbd22ba876ae7309a2b1061a1e9bb063
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vantavo Package Leaflet for language da"
Description: "ePI document Bundle for vantavo Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-bbd22ba876ae7309a2b1061a1e9bb063"
* entry[0].resource = composition-da-bbd22ba876ae7309a2b1061a1e9bb063

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpbbd22ba876ae7309a2b1061a1e9bb063"
* entry[=].resource = mpbbd22ba876ae7309a2b1061a1e9bb063
                            
                    



Instance: mpbbd22ba876ae7309a2b1061a1e9bb063
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product VANTAVO 70 mg/2800 IU tablets"
Description: "VANTAVO 70 mg/2800 IU tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/09/572/001 – 2 tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "VANTAVO 70 mg/2800 IU tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: bbd22ba876ae7309a2b1061a1e9bb063ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "vantavo"

* status = #current
* mode = #working

* title = "List of all ePIs associated with vantavo"

* subject = Reference(mpbbd22ba876ae7309a2b1061a1e9bb063)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#vantavo "vantavo"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-bbd22ba876ae7309a2b1061a1e9bb063) // vantavo en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-bbd22ba876ae7309a2b1061a1e9bb063) // vantavo da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-bbd22ba876ae7309a2b1061a1e9bb063
InstanceOf: List

* insert bbd22ba876ae7309a2b1061a1e9bb063ListRuleset
    